These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 32838682)

  • 1. Pazopanib-related secondary polycythemia in metastatic myxofibrosarcoma: A case report and review of the literature.
    Fanelli M; Caputo F; Cerma K; Gelsomino F; Bari A; Dominici M; Pozzi S
    J Oncol Pharm Pract; 2021 Apr; 27(3):766-770. PubMed ID: 32838682
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pazopanib for metastatic soft-tissue sarcoma: A multicenter retrospective study.
    Koca S; Beşiroğlu M; Özçelik M; Karaca M; Bilici M; Hacıoğlu B; Doğu GG; Kaplan NB; Oruç Z; Aydın D; Dane F
    J Oncol Pharm Pract; 2021 Apr; 27(3):541-546. PubMed ID: 32419618
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pazopanib and soft-tissue sarcomas. Too toxic.
    Prescrire Int; 2013 Jun; 22(139):145-7. PubMed ID: 23866345
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Posterior reversible encephalopathy syndrome (PRES) induced by pazopanib, a multi-targeting tyrosine kinase inhibitor, in a patient with soft-tissue sarcoma: case report and review of the literature.
    Deguchi S; Mitsuya K; Nakasu Y; Hayashi N; Katagiri H; Murata H; Wasa J; Takahashi M; Endo M
    Invest New Drugs; 2018 Apr; 36(2):346-349. PubMed ID: 29067537
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Successful re-administration of Pazopanib in a patient with metastatic renal cell carcinoma and a history of Pazopanib-induced nephrotic syndrome: a case report.
    Jeon SY; Lee NR; Yim CY
    BMC Nephrol; 2019 Jan; 20(1):1. PubMed ID: 30606155
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An unexpected skin ulcer and soft tissue necrosis after the nonconcurrent combination of proton beam therapy and pazopanib: A case of myxofibrosarcoma.
    Uwa N; Terada T; Mohri T; Tsukamoto Y; Futani H; Demizu Y; Okimoto T; Sakagami M
    Auris Nasus Larynx; 2017 Aug; 44(4):484-488. PubMed ID: 27523716
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pazopanib-induced fatal heart failure in a patient with unresectable soft tissue sarcoma and review of literature.
    Karaağaç M; Eryılmaz MK
    J Oncol Pharm Pract; 2020 Apr; 26(3):768-774. PubMed ID: 31547750
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pazopanib efficacy and toxicity in a metastatic sarcoma cohort: Are Indian patients different?
    Sharma A; Vanidassane I; Aggarwal A; Mridha AR; Pandey R; Dhamija E; Barwad A; Rastogi S
    Indian J Cancer; 2019; 56(3):207-210. PubMed ID: 31389382
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic drug evaluation of pazopanib for the treatment of uterine leiomyosarcomas.
    Ferrero S; Leone Roberti Maggiore U; Aiello N; Barra F; Ditto A; Bogani G; Raspagliesi F; Lorusso D
    Expert Opin Drug Metab Toxicol; 2017 Aug; 13(8):881-889. PubMed ID: 28678537
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pembrolizumab- and/or pazopanib-induced remitting seronegative symmetrical synovitis with pitting edema in a patient with renal cell carcinoma.
    Bas O; Ozbek A; Guven D; Aktepe O; Kılıc L; Kertmen N; Erman M
    J Oncol Pharm Pract; 2020 Jul; 26(5):1230-1233. PubMed ID: 31735133
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The clinical outcome of pazopanib treatment in Japanese patients with relapsed soft tissue sarcoma: A Japanese Musculoskeletal Oncology Group (JMOG) study.
    Nakamura T; Matsumine A; Kawai A; Araki N; Goto T; Yonemoto T; Sugiura H; Nishida Y; Hiraga H; Honoki K; Yasuda T; Boku S; Sudo A; Ueda T
    Cancer; 2016 May; 122(9):1408-16. PubMed ID: 26970174
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pazopanib-associated interstitial lung disease in a patient with renal cell carcinoma.
    Harada Y; Kakimoto S; Shimizu T
    BMJ Case Rep; 2020 Jul; 13(7):. PubMed ID: 32641305
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incidence of pneumothorax in advanced and/or metastatic soft tissue sarcoma patients during pazopanib treatment.
    Nakano K; Inagaki L; Tomomatsu J; Motoi N; Gokita T; Ae K; Tanizawa T; Shimoji T; Matsumoto S; Takahashi S
    Clin Oncol (R Coll Radiol); 2014 Jun; 26(6):357. PubMed ID: 24630810
    [No Abstract]   [Full Text] [Related]  

  • 14. Pazopanib, a new therapy for metastatic soft tissue sarcoma.
    Verweij J; Sleijfer S
    Expert Opin Pharmacother; 2013 May; 14(7):929-35. PubMed ID: 23488774
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pazopanib plus best supportive care versus best supportive care alone in advanced gastrointestinal stromal tumours resistant to imatinib and sunitinib (PAZOGIST): a randomised, multicentre, open-label phase 2 trial.
    Mir O; Cropet C; Toulmonde M; Cesne AL; Molimard M; Bompas E; Cassier P; Ray-Coquard I; Rios M; Adenis A; Italiano A; Bouché O; Chauzit E; Duffaud F; Bertucci F; Isambert N; Gautier J; Blay JY; Pérol D;
    Lancet Oncol; 2016 May; 17(5):632-41. PubMed ID: 27068858
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hypertension (HTN) as a potential biomarker of efficacy in pazopanib-treated patients with advanced non-adipocytic soft tissue sarcoma. A retrospective study based on European Organisation for Research and Treatment of Cancer (EORTC) 62043 and 62072 trials.
    Duffaud F; Sleijfer S; Litière S; Ray-Coquard I; Le Cesne A; Papai Z; Judson I; Schöffski P; Chawla SP; Dewji R; Marreaud S; Verweij J; van der Graaf WT
    Eur J Cancer; 2015 Nov; 51(17):2615-23. PubMed ID: 26321011
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sustained erythrocytosis due to the use of Lenvatinib.
    Kaur J; Tuler S; Dasanu CA
    J Oncol Pharm Pract; 2022 Mar; 28(2):475-478. PubMed ID: 34665694
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Harnessing soft tissue sarcoma with low-dose pazopanib - a matter of blood levels.
    Groenland SL; Katz D; Huitema ADR; Steeghs N
    BMC Cancer; 2018 Dec; 18(1):1200. PubMed ID: 30509247
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rapid hair depigmentation in patient treated with pazopanib.
    Šeparović R; Pavlović M; Silovski T; Tečić Vuger A
    BMJ Case Rep; 2018 Aug; 2018():. PubMed ID: 30139781
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Pazopanib for treatment of renal cell carcinoma and soft tissue sarcomas].
    Brotelle T; Bay JO
    Bull Cancer; 2014 Jun; 101(6):641-6. PubMed ID: 24977453
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.